WHO ICTRP trial
Prospective, Multicenter, Randomized, Dual-Cohort Clinical Study of Irinotecan…
ChiCTR2500105112 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2500105112 |
|---|---|
| Public title | Prospective, Multicenter, Randomized, Dual-Cohort Clinical Study of Irinotecan Liposome (II) Plus Oxaliplatin Combined with Tegafur-Gimeracil-Oteracil Potassium (SOX) versus 5-Fluorouracil/Leucovorin (5-FU/LV) in Perioperative Treatment of Borderline Resectable Pancreatic Cancer |
| Scientific title | Prospective, Multicenter, Randomized, Dual-Cohort Clinical Study of Irinotecan Liposome (II) Plus Oxaliplatin Combined with Tegafur-Gimeracil-Oteracil Potassium (SOX) versus 5-Fluorouracil/Leucovorin (5-FU/LV) in Perioperative Treatment of Borderline Resectable Pancreatic Cancer |
| Primary sponsor | Ruijin Hospital, Shanghai Jiao Tong University School of Medicine |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Countries | China |
| Conditions | Boarderline resectable pancreatic cancer |
| Interventions | Experimental group:NASOX;Control group:NALIRIFOX |
| Registration date | Jun 30, 2025 |
| Target size | Experimental group:181;Control group:181 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: